<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859128</url>
  </required_header>
  <id_info>
    <org_study_id>JS001-016-III-HCC</org_study_id>
    <nct_id>NCT03859128</nct_id>
  </id_info>
  <brief_title>Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Curative Hepatic Resection</brief_title>
  <acronym>JUPITER 04</acronym>
  <official_title>A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Toripalimab (Recombinant Humanized Anti-PD-1 Monoclonal Antibody, JS001) / Placebo as Adjuvant Therapy in Patients With Local Advanced Hepatocellular Carcinoma After Curative Hepatic Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate if Toripalimab (A PD-1 Inhibitor) will improve recurrence-free
      survival (RFS) compared to placebo in participants with HCC and are at high risk of
      recurrence after complete resection with no residual of tumour.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">April 12, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 24, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RFS(Recurrence free survival)</measure>
    <time_frame>up to 44 months</time_frame>
    <description>Defined as the time from randomization to the first documented disease recourrence or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TTR(Time to recurrence)</measure>
    <time_frame>up to 44 months</time_frame>
    <description>Define as the time from randomization to the first documented disease recourrence or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTLR(Time to local recurrence)</measure>
    <time_frame>up to 44 months</time_frame>
    <description>Define as the time from randomization to the first documented local disease recourrence or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS(Overall survival)</measure>
    <time_frame>up to 60 months</time_frame>
    <description>Defined as time from randomization and the date of death.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">402</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TORIPALIMAB 240mg ,Q3W, up to 48 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 240mg Q3W, up to 48 Weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TORIPALIMAB INJECTION(JS001 )</intervention_name>
    <description>Arm A: Toripalimab 240mg IV(Injection of Vein) Q3W Arm B: Placebo 240mg IV(Injection of Vein) Q3W</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HCC with at least one protocol defined risk factor, diagnosed confirmed by central
             pathological review and received R0 resection;

          2. BICR confirmed no resdual tumor lesions are detected in liver;

          3. Child-Puch score, Class A;

          4. ECOG score is 0;

        Exclusion Criteria:

          1. Patients previously received PD-1 antibody, PD-L1 antibody, PD-L2 antibody or CTLA-4
             antibodies, including those who have participated in the JS001 clinical study;

          2. Portal vein tumor thrombi or liver metastases or recurrent liver cancer;

          3. With symptoms of central nervous system metastasis;

          4. With any history of active autoimmune disease or autoimmune disease;

          5. Known liver diseases with clinical significance;

          6. Patients infected by hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D
             virus (HDV):

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jia Fan, Prof</last_name>
    <phone>+86 13601669720</phone>
    <email>fan.jia@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital,Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 18, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

